The contractor shall provide enhanced analysis of clinical and specimen-derived data on all patients seen at VA network hospitals who have a cancer diagnosis. The contractor shall furnish a robust,…
Ended Awarded Last action
- Contract number
- VA24114J2151
- Awardee
-
Personalis, Inc. UEI UKTDBM9KX1V8
- Awarding agency
-
Veterans Integrated Service Network 1
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $240,250
Award facts
- Contract value 100% obligated
- $240,250.00 Current and potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- NAICS code
- 541711 Research and Development in Biotechnology
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 4 offers Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Menlo Park, CA 94025, USA
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$59,750 | |
| Original award | $300,000 |
Description
The contractor shall provide enhanced analysis of clinical and specimen-derived data on all patients seen at VA network hospitals who have a cancer diagnosis. The contractor shall furnish a robust, scalable, dynamic, secure, innovative solutions of analyzing samples obtained during regular clinical care such as tissues from biopsy - using new genomic assay technology. The clia vendor shall provide emerging technologies to improve oncology care for all patients within the VA healthcare system. The contractor shall provide targeted sequencing of DNA fragments known to harbor mutations in cancer specimens (commonly referred to as a mutation panel). The number of DNA segments sequenced varies by the laboratory and assay performed. Mutations in the DNA can either be inferred against a laboratory `reference sequence or can be determined by sequencing of patient germ-line DNA obtained from adjacent normal tissue or peripheral blood. The contractors shall provide sequencing of the whole exome of cancer specimens, with mutations identified by comparison against a laboratory `reference sequence or germ-line DNA as described above. The contracotr shall provide sequencing of the cancer specimen RNA or `transcriptome . This strategy can be combined with either targeted or whole exome DNA sequencing. Products of the testing returned to the VA include all sequence data including raw test data (fast-Q, BAM, read quality files and variant call files) and a report of important mutations and their significance to be returned to the medical record. Mutations found in the tumor sample will be annotated so that clinicians can gain an understanding of their meaning. The laboratory shall specify how this annotation will be performed and in particular, what knowledge base will be used to generate the annotations. The contractor shall maintains an up-to-date knowledge base and must be able to update annotations of a patient report upon request. The contractor shall at all times manintain a secure environment and practice covering all protected health information (PHI).
Quick answers
Who was awarded contract VA24114J2151?
VA24114J2151 was awarded to Personalis, Inc. by Veterans Integrated Service Network 1 (Veterans Health Administration) on September 30, 2014.
How much is contract VA24114J2151 worth?
The government has obligated $240,250 on VA24114J2151.
Is contract VA24114J2151 an order under another contract?
Yes. VA24114J2151 is a delivery order under VA24114D0178, an indefinite delivery contract.
Was contract VA24114J2151 competed?
The extent of competition for VA24114J2151 was competed under sap. The government received 4 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award